Peter Lewis
Global Neurodegeneration Translator
Rosetta Therapeutics


Research Interests: Research interests include neurodegeneration; the structure and function of chromosomes with specific reference to gene regulation; and protein folding.

Bio Brief

An accomplished biochemist, Dr. Lewis studies neurodegeneration, chromosome structure and function, gene regulation, and protein folding. As CEO and co-founder of Rosetta Therapeutics, he is creating new matter to find a cure for neurodegenerative diseases such as ALS, Alzheimer’s, and Parkinson’s diseases. Dr. Lewis is a global educator. He has been an academic leader and faculty member at U of T since 1974. He served as Associate Vice President, Research and Innovation specializing in Global Research Partnerships from 2010 until 2016. Prior to that he served as Vice Dean of Research and International Relations in the Faculty of Medicine for seven years.

Other Highlights:

TRP Job Opportunities

Want to join the TRP team? We're hiring additional positions for the upcoming Term.  All instruction will be online and so a good working knowledge of Zoom and Quercus (UofT's LMS) is an asset for prospective team members.  Classes will range from 12 to 35 students...

2021 Orientation Spotlight: Fireside Chat with Jamie L. Block

In September 2021, we held our Fall orientation, complete with hands-on activities in an engaging virtual format. Throughout the sessions, our new batch of translational researchers had a chance to engage with the faculty, the TPR community, and their peers. Providing...

Spread the word about the TRP!

Download our program brochure to share with your contacts.